Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer

Raghavendra Vasudeva Murthy, Gunnar Arbman, Jingfang Gao, G. David Roodman, Xiao Feng Sun

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Purpose: Legumain, a novel asparaginyl endopeptidase, has been observed to be highly expressed in several types of tumors including colorectal cancer. However, there is no study examining the relationship of legumain expression to clinocopatbologic and biological variables in colorectal cancers. Experimental Design: We investigated legumain expression in 164 primary colorectal cancers, 34 corresponding distant normal mucosa samples, 89 adjacent normal mucosa samples, and 33 lymph node metastases using immunohistochemistry. We also did Western blotting analysis on three additional colorectal cancers and three colonic cell lines. Results: Legumain expression was increased in primary tumors compared with distant or adjacent normal mucosa (P <0.05), but there was no significant change between primary tumors and metastases (P > 0.05). Legumain expression was positively related to poorer differentiation/ mucinous carcinoma (P = 0.04), higher degree of necrosis (P = 0.03) and apoptosis (P <0.0001), positive proliferating cell nuclear antigen (P <0.0001) and p53 expression (P = 0.049), and had a positive tendency towards stromelysin 3 (P = 0.058) and PINCH positivity (P = 0.05). The patients with tumors that showed both weak and lower percentage of the legumain expression, either in tumor (P = 0.01) or in stroma (P = 0.04), had a better prognosis. Conclusions: The legumain expression may be involved in colorectal cancer development and have a prognostic value in the patients.

Original languageEnglish (US)
Pages (from-to)2293-2299
Number of pages7
JournalClinical Cancer Research
Volume11
Issue number6
DOIs
StatePublished - Mar 15 2005
Externally publishedYes

Fingerprint

asparaginylendopeptidase
Colorectal Neoplasms
Mucous Membrane
Neoplasms
Matrix Metalloproteinase 11
Mucinous Adenocarcinoma
Proliferating Cell Nuclear Antigen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer. / Murthy, Raghavendra Vasudeva; Arbman, Gunnar; Gao, Jingfang; Roodman, G. David; Sun, Xiao Feng.

In: Clinical Cancer Research, Vol. 11, No. 6, 15.03.2005, p. 2293-2299.

Research output: Contribution to journalArticle

Murthy, Raghavendra Vasudeva ; Arbman, Gunnar ; Gao, Jingfang ; Roodman, G. David ; Sun, Xiao Feng. / Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer. In: Clinical Cancer Research. 2005 ; Vol. 11, No. 6. pp. 2293-2299.
@article{ed1e9b660ae346f9b324eb63ed66b4bd,
title = "Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer",
abstract = "Purpose: Legumain, a novel asparaginyl endopeptidase, has been observed to be highly expressed in several types of tumors including colorectal cancer. However, there is no study examining the relationship of legumain expression to clinocopatbologic and biological variables in colorectal cancers. Experimental Design: We investigated legumain expression in 164 primary colorectal cancers, 34 corresponding distant normal mucosa samples, 89 adjacent normal mucosa samples, and 33 lymph node metastases using immunohistochemistry. We also did Western blotting analysis on three additional colorectal cancers and three colonic cell lines. Results: Legumain expression was increased in primary tumors compared with distant or adjacent normal mucosa (P <0.05), but there was no significant change between primary tumors and metastases (P > 0.05). Legumain expression was positively related to poorer differentiation/ mucinous carcinoma (P = 0.04), higher degree of necrosis (P = 0.03) and apoptosis (P <0.0001), positive proliferating cell nuclear antigen (P <0.0001) and p53 expression (P = 0.049), and had a positive tendency towards stromelysin 3 (P = 0.058) and PINCH positivity (P = 0.05). The patients with tumors that showed both weak and lower percentage of the legumain expression, either in tumor (P = 0.01) or in stroma (P = 0.04), had a better prognosis. Conclusions: The legumain expression may be involved in colorectal cancer development and have a prognostic value in the patients.",
author = "Murthy, {Raghavendra Vasudeva} and Gunnar Arbman and Jingfang Gao and Roodman, {G. David} and Sun, {Xiao Feng}",
year = "2005",
month = "3",
day = "15",
doi = "10.1158/1078-0432.CCR-04-1642",
language = "English (US)",
volume = "11",
pages = "2293--2299",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer

AU - Murthy, Raghavendra Vasudeva

AU - Arbman, Gunnar

AU - Gao, Jingfang

AU - Roodman, G. David

AU - Sun, Xiao Feng

PY - 2005/3/15

Y1 - 2005/3/15

N2 - Purpose: Legumain, a novel asparaginyl endopeptidase, has been observed to be highly expressed in several types of tumors including colorectal cancer. However, there is no study examining the relationship of legumain expression to clinocopatbologic and biological variables in colorectal cancers. Experimental Design: We investigated legumain expression in 164 primary colorectal cancers, 34 corresponding distant normal mucosa samples, 89 adjacent normal mucosa samples, and 33 lymph node metastases using immunohistochemistry. We also did Western blotting analysis on three additional colorectal cancers and three colonic cell lines. Results: Legumain expression was increased in primary tumors compared with distant or adjacent normal mucosa (P <0.05), but there was no significant change between primary tumors and metastases (P > 0.05). Legumain expression was positively related to poorer differentiation/ mucinous carcinoma (P = 0.04), higher degree of necrosis (P = 0.03) and apoptosis (P <0.0001), positive proliferating cell nuclear antigen (P <0.0001) and p53 expression (P = 0.049), and had a positive tendency towards stromelysin 3 (P = 0.058) and PINCH positivity (P = 0.05). The patients with tumors that showed both weak and lower percentage of the legumain expression, either in tumor (P = 0.01) or in stroma (P = 0.04), had a better prognosis. Conclusions: The legumain expression may be involved in colorectal cancer development and have a prognostic value in the patients.

AB - Purpose: Legumain, a novel asparaginyl endopeptidase, has been observed to be highly expressed in several types of tumors including colorectal cancer. However, there is no study examining the relationship of legumain expression to clinocopatbologic and biological variables in colorectal cancers. Experimental Design: We investigated legumain expression in 164 primary colorectal cancers, 34 corresponding distant normal mucosa samples, 89 adjacent normal mucosa samples, and 33 lymph node metastases using immunohistochemistry. We also did Western blotting analysis on three additional colorectal cancers and three colonic cell lines. Results: Legumain expression was increased in primary tumors compared with distant or adjacent normal mucosa (P <0.05), but there was no significant change between primary tumors and metastases (P > 0.05). Legumain expression was positively related to poorer differentiation/ mucinous carcinoma (P = 0.04), higher degree of necrosis (P = 0.03) and apoptosis (P <0.0001), positive proliferating cell nuclear antigen (P <0.0001) and p53 expression (P = 0.049), and had a positive tendency towards stromelysin 3 (P = 0.058) and PINCH positivity (P = 0.05). The patients with tumors that showed both weak and lower percentage of the legumain expression, either in tumor (P = 0.01) or in stroma (P = 0.04), had a better prognosis. Conclusions: The legumain expression may be involved in colorectal cancer development and have a prognostic value in the patients.

UR - http://www.scopus.com/inward/record.url?scp=16844367758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16844367758&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-1642

DO - 10.1158/1078-0432.CCR-04-1642

M3 - Article

C2 - 15788679

AN - SCOPUS:16844367758

VL - 11

SP - 2293

EP - 2299

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -